Personalized management: inoperable gastrointestinal stromal tumors

Susie Bae1, Jayesh Desai2

  • 1Australasian Sarcoma Study Group and Peter MacCallum Cancer Centre, Melbourne, Australia.

Summary

Tyrosine kinase inhibitors (TKIs) have revolutionized gastrointestinal stromal tumors (GIST) treatment, improving survival. Optimizing current therapies through molecular tools and multidisciplinary approaches is key for managing GIST resistance.